The Uromigos
The Uromigos
Advertisement
The UromigosThe Uromigos | May 20, 2024
Silke Gillessen joins Brian and Tom to give a preview of this year's ASCO annual meeting.
Listen Now
The UromigosThe Uromigos | May 20, 2024
Dr. Nick James joins the podcast to discuss the recent Lancet Commission paper on prostate cancer.
The UromigosThe Uromigos | May 4, 2024
Tom and Brian are joined by David Penson to discuss upcoming presentations to look forward to at AUA.
The UromigosThe Uromigos | April 30, 2024
Dr. Silke Gillessen gives a summary of APCCC 2024, including surgery versus RT, genetic and somatic testing, and more.
The UromigosThe Uromigos | April 30, 2024
Chris Sweeney is joined by fellow experts to discuss mHSPC side effects such as bone weakness, hot flashes, and gynecomastia.
The UromigosThe Uromigos | April 30, 2024
Professor Thomas Suter and Dr. Chuck Ryan discuss cardiovascular risks associated with hormone therapy in prostate cancer.
The UromigosThe Uromigos | April 30, 2024
Drs. Thomas Zilli and Pierre Blanchard debate the use of radiation therapy in prostate cancer and oligometastatic disease.
The UromigosThe Uromigos | April 30, 2024
Brian and Tom speak with Drs. Piet Ost and Jason Efstathiou on the data for and against radiation therapy in prostate cancer.
The UromigosThe Uromigos | April 26, 2024
Alison Birtle gives an update on the POUT trial on the use of adjuvant chemotherapy after nephroureterectomy for UTUC.
The UromigosThe Uromigos | April 18, 2024
Daniel Goldstein returns to the podcast to discuss dosing changes in drugs such as nivolumab and pembrolizumab.
The UromigosThe Uromigos | April 8, 2024
Dr. Galsky describes the OS signal data from CheckMate-274 on adjuvant nivolumab for muscle-invasive bladder cancer.
The UromigosThe Uromigos | April 8, 2024
Dr. Matt Galsky, Brian, and Tom discuss the IMvigor011 trial data that was presented at EAU 2024.
The UromigosThe Uromigos | April 4, 2024
Michiel Van der Heijdan explores the role of radiotherapy and other neoadjuvant combinations for MIBC.
The UromigosThe Uromigos | March 29, 2024
Dr. Galsky discusses his phase 2 study evaluating the effects of gem/cis/nivo followed by nivolumab in responders.
The UromigosThe Uromigos | April 18, 2024
FDA Deputy Oncology Director Dan Suzman describes approaches to oncology trials in the GU setting.
The UromigosThe Uromigos | March 14, 2024
Dr. Tanya Dorff discusses her work on a phase 1 study investigating acapatamab for advanced prostate cancer.
The UromigosThe Uromigos | March 8, 2024
Michael Lattanzi, MD, joins the podcast to discuss treatment plans and research in the community oncology setting.
The UromigosThe Uromigos | March 14, 2024
The Uromigos discuss adjuvant therapy in kidney and bladder cancer trials including KEYNOTE-564.
The UromigosThe Uromigos | February 26, 2024
Vania Wisdom, Senior Executive Editor at The Lancet, discusses cancer treatment and research in developing countries.
The UromigosThe Uromigos | March 14, 2024
Dr. McDermott discusses the similarities between current melanoma trials and kidney cancer treatments.
Advertisement
Advertisement
Advertisement